NAMS vs MDGL vs MRK vs ARWR vs AMGN

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -50. 6% for NewAmsterdam Pharma Company N. V. (NAMS). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 3x trailing P/E (21. 7x forward), making it the more compelling value choice. Analysts rate NewAmsterdam Pharma Company N. V. (NAMS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 3x versus Amgen Inc. at 22. 9x. On forward P/E, Amgen Inc. is actually cheaper at 14. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Merck & Co. , Inc. wins at 1. 02x versus Amgen Inc. 's 4. 96x — a reasonable growth-adjusted valuation.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +290. 8%, compared to +5. 0% for Arrowhead Pharmaceuticals, Inc. (ARWR). Over 10 years, the gap is even starker: MDGL returned +37. 4% versus AMGN's +159. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 38β versus Arrowhead Pharmaceuticals, Inc. 's 1. 70β — meaning ARWR is approximately 341% more volatile than MRK relative to the S&P 500. On balance sheet safety, NewAmsterdam Pharma Company N. V. (NAMS) carries a lower debt/equity ratio of 0% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -50. 6% for NewAmsterdam Pharma Company N. V. (NAMS). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to 8. 0% for Merck & Co. , Inc.. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -905. 7% for NewAmsterdam Pharma Company N. V. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -1002. 9% for NAMS. At the gross margin level — before operating expenses — ARWR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Merck & Co. , Inc. (MRK) is the more undervalued stock at a PEG of 1. 02x versus Amgen Inc. 's 4. 96x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Amgen Inc. (AMGN) trades at 14. 6x forward P/E versus 21. 7x for Merck & Co. , Inc. — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDGL: 36. 0% to $712. 00.

In this comparison, MRK (2.

9% yield), AMGN (2. 9% yield) pay a dividend. NAMS, MDGL, ARWR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 38), 2. 9% yield, +162. 0% 10Y return). Both have compounded well over 10 years (MRK: +162. 0%, NAMS: +234. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NAMS is a small-cap quality compounder stock; MDGL is a mid-cap high-growth stock; MRK is a large-cap deep-value stock; ARWR is a mid-cap high-growth stock; AMGN is a mid-cap quality compounder stock. MRK, AMGN pay a dividend while NAMS, MDGL, ARWR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.